Total Funding
87
78
Total FundingVenture - Series Unknown raised
Growth Score 87 in past quarter
-4 pts
Heat Score 78 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
60142
Serinus Biosciences develops technologies to understand how chemicals work inside malignant tumor cells.
- Adam Yaari: CEO
- Maxwell Sherman: CTO
About the Company
Serinus Biosciences develops technologies to understand how chemicals work inside malignant tumor cells. They are developing a new generation of AI for drug development by leveraging knowledge-primed models and cancer biology. Their technique makes it possible to create medicines that are effective for a variety of patient groups, bypass resistance
mechanisms, and support combinations by design.
Serinus Biosciences is headquartered in New York City, New York and was founded in 2022.